18F-FDG PET在头颈癌中的预后作用取决于HPV状态
该研究回顾166例接受放化疗前FDG PET/CT规划的头颈癌病例,评估PET参数联合临床因素及HPV状态的预后价值。以无病生存为终点,单因素分析中所有FDG PET参数均不显著,仅HPV状态、ECOG状态和CT来源的GTV-U显著(p<0.01);仅在HPV无关头颈癌亚组(n=73)中,多因素模型加入MTV可改善预测(p<0.001)。结论认为FDG PET参数对头颈癌放化疗总体预后评估价值有限,但在HPV无关头颈癌中与生存关联较强,CT来源肿瘤体积通常比FDG PET/CT衍生参数与结局更密切。
要点
- 单因素分析中FDG PET参数对DFS均不显著,HPV状态、ECOG和GTV-U显著(p<0.01)。
- 仅在HPV无关头颈癌亚组(n=73)中,多因素模型加入MTV可改善预测(p<0.001)。
- CT来源肿瘤体积通常比FDG PET/CT参数与结局更密切。
核心结论
- FDG PET参数对头颈癌放化疗总体预后评估价值有限,但在HPV无关头颈癌中与生存关联较强。
- CT来源肿瘤体积通常比FDG PET/CT衍生参数与结局更密切。
研究设计与样本
- 回顾性分析166例接受放疗规划FDG PET/CT扫描的头颈癌病例,所有患者接受68-70 Gy放疗±同步顺铂。
- 主要终点为无病生存(DFS)。
主要发现
- 166例中48例出现局部区域复发、23例出现转移复发。
- 单因素分析以DFS为终点时,所有FDG PET参数均不显著;HPV状态、ECOG状态和GTV-U(原发肿瘤及淋巴结CT体积)显著(p<0.01)。
- 仅在HPV无关头颈癌亚组(HPV阴性口咽癌及非口咽癌;n=73)中,多因素模型加入MTV可改善预测(p<0.001)。
- DFS事件在HPV相关头颈癌中为29例(31%),在HPV无关头颈癌中为53例(73%)。
关键数值与推荐
- 放疗剂量68-70 Gy,±同步顺铂。
- 单因素分析中HPV状态、ECOG状态和GTV-U显著(p<0.01)。
- HPV无关头颈癌亚组多因素模型加入MTV改善预测(p<0.001)。
临床怎么用
- 头颈癌放化疗前FDG PET参数不宜单独用于总体预后分层。
- 应结合HPV状态、ECOG状态和CT来源肿瘤体积进行预后评估。
- 在HPV无关头颈癌患者中,可考虑将MTV纳入预后模型。
局限性
- 回顾性研究设计。
- HPV无关亚组样本量有限(n=73)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Standardized uptake value (SUV) and related parameters derived from 2-deoxy-2-[18F]-fluoro-d-glucose (FDG) PET/CT prior to radiochemotherapy of head and neck cancer (HNC) were significantly associated with survival in a number of studies. The aim of this study was to validate these findings and to evaluate the prognostic role of PET parameters also including clinical factors and HPV status. MATERIALS AND METHODS: We reviewed 166 HNC cases with a radiotherapy planning FDG PET/CT scan. All patients received radiotherapy, 68-70 Gy with or without concomitant cisplatin. Primary endpoint was disease-free survival (DFS). Twelve clinical factors, including HPV, performance status, stage and treatment parameters and ten PET/CT image parameters including gross tumor volume (GTV), metastatic lymph node volume, SUVmax, metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were collected. Univariate and multivariate Cox regression analyses were employed. RESULTS: Of the 166 patients included, 48 had locoregional and 23 had metastatic recurrence. None of the FDG PET parameters were significant in the univariate analysis using DFS as endpoint. HPV status, ECOG status and GTV-U (primary tumor and lymph node volume from CT) were statistically significant (p < 0.01). Only in the subgroup of HPV-unrelated HNC (HPV negative oropharyngeal cancer [OPC] and non-OPC; n = 73), the multivariate model could be improved by including MTV (p < 0.001). DFS events were 29 (31%) in HPV-related and 53 (73%) in HPV-unrelated HNC. CONCLUSION: FDG PET parameters appear less important for overall prognostication of radiochemotherapy outcome for HNC. Still, the association between the FDG PET parameters and survival is strong for HNC not related to HPV. Tumor volume from CT is generally more closely related to outcome than parameters derived from FDG PET/CT.
引用
- Moan JM, Amdal CD, Malinen E, et al. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status. Radiother Oncol. 2019. PMID: 31177043. doi:10.1016/j.radonc.2019.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。